WELCOME TO EVEN CAPITAL.
Venture capital for women, by women.

Our mission is simple.

Close a gap that unfairly disadvantages women by funding the future through significant investments.

Less than 3% of the world’s venture capital funding goes to female-founded businesses.

Between 2017 and 2021, female founders received less than 1.5% of the total capital raised by European start-ups.

Despite inequality in funding, women-led startups generate 10% more in cumulative revenue over a 5-year period.

Start-ups with a female founder generated 78 cents of revenue for every $1 of funding, while male-founded startups generated 31 cents (BCG).

The traditional venture capital ecosystem is teeming with obstacles for women, & none more frustrating or unfair than the lack of funding going to female business founders.

It’s time to even out the balance.

Latest News
Meet Our Partners

Sharesies

Sharesies’ purpose is to create the most financially empowered generation. As the most popular and fastest growing investment platform in Aotearoa, Sharesies provides more than 440,000 people with access to global shares with no minimum investment.

We want Australians to have access to the same money opportunities that we’ve successfully provided in Aotearoa. Even Capital’s investment in Sharesies has helped to grow the Sharesies brand globally, starting with launching in Australia.

Investment: Series A 2020, Series B 2021.

 

Orbis Diagnostics

Orbis Diagnostics believes making complex medical testing simple and accessible whenever and wherever needed is key to overcoming some of the world’s biggest challenges.

Since establishment in 2016, Orbis has demonstrated the agility of its platform technology to miniaturise and simplify lab tests for both animal and human health applications. Orbis is establishing channels of sale through nationwide pharmacies and government to make its immunity test widely accessible for its customers. Orbis has partnered with IDEMIA, a globally leading biometrics specialist to integrate the Orbis solution with IDEMIA’s digital identity credential innovations trusted by governments and health providers around the world.

Even Capital’s investment will be used to advance the productisation of Orbis’ technology and allow Orbis to reach market entry.

Investment: Seed 2021, Seed 2022.

 

Easy Crypto

Established in 2018, Easy Crypto offers a secure, simple and easy-to-understand way to get involved in the cryptocurrency market, with a mission to democratise finance by providing access to financial products and services enabled by blockchain technology.

Even Capital’s Series A investment in Easy Crypto will expand the range of products and services available, and support growth globally. Currently operating in four markets, and seeking to expand further in the Southern Hemisphere, Easy Crypto has a particular interest in countries with low rates of banking access.

Investment: Series A 2021, Pre-Series B 2022.

 

Baymatob

Founded after a traumatic birth experience, mechatronic engineer and mother Dr Sarah McDonald created Baymatob, an AI-guided maternal and fetal diagnostics company based in Australia with a passion for addressing unmet needs in women’s health. 

Baymatob’s innovative wearable device Oli uses artificial intelligence to identify mothers during labor who are at high risk of developing postpartum haemorrhage (PPH) well before giving birth. 

PPH, or heavy bleeding after childbirth, is a serious complication of pregnancy and is the world’s leading cause of preventable maternal death. One mother dies every seven minutes due to postpartum haemorrhage globally.

Partnering with Global Bio Fund, Even Capital has invested in Baymatob’s A$4.6m Series A fundraising round to support the inspiring female leadership team and the company’s ongoing in-human clinical development and path to commercialisation for Oli.

Investment: Series A 2022, Series A2 2024.
See our Portfolio